Building an Early Stage Biotech Company on Strong Foundations
The "new normal" is not only causing big pharma firms to adapt their business strategies to current realities (see the cover story in this issue), but it also has cascaded down to impact companies which are just starting out on their journey of drug development. The "new normal" might not seem that much different from previous periods of fiscal constraints the biotech sector has experienced during its history.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST